Language
English
Publication Date
1-1-2024
Journal
Neurotherapeutics
DOI
10.1016/j.neurot.2024.e00316
PMID
38244259
PMCID
PMC10903096
PubMedCentral® Posted Date
1-19-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Mitochondria are critical for brain development and homeostasis. Therefore, pathogenic variation in the mitochondrial or nuclear genome which disrupts mitochondrial function frequently results in developmental disorders and neurodegeneration at the organismal level. Large-scale application of genome-wide technologies to individuals with mitochondrial diseases has dramatically accelerated identification of mitochondrial disease-gene associations in humans. Multi-omic and high-throughput studies involving transcriptomics, proteomics, metabolomics, and saturation genome editing are providing deeper insights into the functional consequence of mitochondrial genomic variation. Integration of deep phenotypic and genomic data through allelic series continues to uncover novel mitochondrial functions and permit mitochondrial gene function dissection on an unprecedented scale. Finally, mitochondrial disease-gene associations illuminate disease mechanisms and thereby direct therapeutic strategies involving small molecules and RNA-DNA therapeutics. This review summarizes progress in functional genomics and small molecule therapeutics in mitochondrial neurodevelopmental disorders.
Keywords
Humans, Genomics, Proteomics, Mitochondria, Mitochondrial Diseases, Neurodevelopmental Disorders, Mitochondrial disease, Functional genomics, Neurodevelopmental disorders, Small molecules, Therapeutics
Published Open-Access
yes
Recommended Citation
, "Functional Genomics and Small Molecules in Mitochondrial Neurodevelopmental Disorders" (2024). Faculty, Staff and Students Publications. 3425.
https://digitalcommons.library.tmc.edu/baylor_docs/3425